Effect of mild or moderate hepatic impairment on the pharmacokinetics of risdiplam

AIM: This phase I, multicentre, open‐label, nonrandomised, parallel‐group, two‐part study aimed to evaluate the effect of mild to moderate hepatic impairment on the pharmacokinetics (PK), safety and tolerability of a single oral dose of risdiplam. METHODS: Adult subjects (aged 18‐70 years) with mild...

Descripción completa

Detalles Bibliográficos
Autores principales: Kletzl, Heidemarie, Ajmi, Hassan, Antys, Izabela, Heinig, Katja, Jaber, Birgit, Marbury, Thomas C., Young, Annie, Günther, Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9546347/
https://www.ncbi.nlm.nih.gov/pubmed/35301746
http://dx.doi.org/10.1111/bcp.15319

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9546347/
https://www.ncbi.nlm.nih.gov/pubmed/35301746
http://dx.doi.org/10.1111/bcp.15319

Ejemplares similares